OA13136A - Pulmonary administration of chemically modified insulin. - Google Patents
Pulmonary administration of chemically modified insulin. Download PDFInfo
- Publication number
- OA13136A OA13136A OA1200300305A OA1200300305A OA13136A OA 13136 A OA13136 A OA 13136A OA 1200300305 A OA1200300305 A OA 1200300305A OA 1200300305 A OA1200300305 A OA 1200300305A OA 13136 A OA13136 A OA 13136A
- Authority
- OA
- OAPI
- Prior art keywords
- insulin
- composition
- peg
- polyethylene glycol
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (75)
1 3136 · -62- IT rs CLAIMED:
1. An irssulin composition for puimonary administration, said compositioncoroprising a conjugale of insulin covaientîy coupled to one or more molécules of a non-naturally occurring hydrophilic polymer.
2. The insulin composition of claim 1, whercin said conjugate is absent a lipophiliemoiety.
3. The insulin composition of claim i, wherein said non-naturally occurringhydrophilic polymer is a polyalkyene glycol.
4. The insulin composition of claim i, wherein said non-naturally occurringhydrophilic polymer is polyethylene glycol.
5. The insulin composition of claim 2, wherein said non-naturally occurringhydrophilic polymer is polyethylene glycoi.
6. The composition of claim 4, characterized by an absolute puimonary bioavailability thaï is greater than that of native insulin.
7. The composition of claim 6, characterized by an absolute puimonary bioavailability that is at least twice that of native insulin. S. The composition of claim 4, characterized by an absolute puimonary bioavailability greater than 15%.
9. The composition of claim 8, characterized by an absolute puimonary bioavailability greater than 30%.
10. The composition of claim 4, which when administered to the lung, is characterizedby a Tmax that is at least three times that of native insulin. DUPLICATA 1 3136 · -63-
1 - The composition of daim 10, which when administered to the iung, ischaracterized by a Tmax that is at least five limes that of native insulin.
12. The composition of ciaim 4, wherein said polyethylene giycol is end-capped.
13. The composition of ciaim 12, wherein said polyethylene giycol is end-capped withan alkoxy group.
14. The composition of daim 4, wherein said polyethylene giycol is selected from thegroup consisting of linear polyethylene giycol, branched polyethylene giycol, forkedpolyethylene giycol, and dumbbell polyethylene giycol.
15. The composition of daim 14, wherein said polyethylene giycol comprises abiodégradable linkage. ·
16. The composition of ciaim 14, wherein said polyethylene giycol comprises anumber of (OCH2CH2) subunits selected from the group consisting of from about 2 to 300subunits, from about 4 to 200 subunits, and from about 10 to 100 subunits.
17. The composition of ciaim 14, wherein said polyethylene giycol has a nominalaverage molecular weight from about 200 to about 10,000 daltons.
18. The composition of ciaim 14, wherein said polyethylene giycol is linear.
19. The composition of daim 17, wherein said polyethylene giycol has a nominalaverage molecular weight from about 200 to about 5,000 daltons.
20. The composition of ciaim 17, wherein said polyethylene giycol has a nominalaverage molecular weight from about 200 to about 2,000 daltons.
21. The composition of ciaim 17, wherein said polyethylene giycol has a nominalaverage molecular weight from about 200 to about 1,000 daltons. DUPLICATA -64- 1 3136
22. The composition of claim 4, wherein said insulin is native insulin.
23. The composition of claim 4, wherein said conjugate has a purity of greater than90 %. 5
24. The composition of claim 4, wherein said insulin is covalently coupled topolyethyiene glycol at one or more of its amino sites.
25. The composition of claim 24, wherein at least about 75% of the B-lPhe sites on 10 insulin are covalently coupled to polyethyiene glycol.
26. The composition of claim 25, wherein at least about 90% of the B-lPhe sites oninsulin are covalently coupled to polyethyiene glycol.
27. The composition of claim 24, comprising a mixture of monomer and dimer conjugales of insulin.
28. The composition of claim 27, further comprising a trimer insulin conjugate.
29. The composition of claim 4, wherein said insulin is covalently coupled to polyethyiene glycol via a iinking moiety positioned at a terminus of said polyethyieneglycol.
30. The composition of claim 4, wherein said polyethyiene glycol, prior to coupling 25 with insulin, possesses an activated Iinking moiety at one terminus suitable for covaient coupling with insulin.
31. The composition of claim 30, wherein said activated Iinking moiety is suitable forcoupling with reactive insulin amino groups. 30
32. The composition of claim 31, wherein said activated Iinking moiety comprises areactive functional group selected from the group consisting of N-hydroxysuccinimideactive esters, active carbonates, aldéhydes, and acetais. DUPLICATA -65- 13136,
33. The composition of claim 29, wherein insulin is covalently coupled to poiyethylene glycol via an amide linkage.
34. The composition of claim 4 in aerosolized form.
35. The composition of claim 4 in Iiquid or dry form.
36. The composition of claim 4 further comprising a pharmaceutically acceptableexcipient.
37. The composition of claim 4 in spray-dried form.
38. A method for delivering insulin to a mammalian subject in need thereof, saidmethod comprising: aerosolizing the insulin composition of claim 4, and administering said aerosolized insulin composition by inhalation for déposition inand absorption from the lung of said subject.
39. A method for providing a substantially non-immunogenic insulin composition foradministration to the lung of a subject in need thereof, said method comprising: covalently coupîing insulin to one or more molécules of a non-naturally occurringhydrophilic polymer to provide a composition comprising an insulin-hydrophilic polvmerconjugate, and administering said composition to the lung of a subject in need thereof byinhalation, whereby as a resuit of said administering, said insulin passes through the lungand enters into the blood circulation.
40. The method of claim 39, wherein said non-naturally occurring hydrophilicpolymer is a polyalkylene glycol. DUPLICATA -66- 13136
41. A method for providing a prolonged-effect insulin composition for administrationto the lung of a subject in need thereof, said method comprising: covalently coupiing insulin to one or more molécules of a non-naturally occurringhydrophilic polymer to provide a composition comprising an insulin-hydrophilic polymerconjugate, administering said composition to the lung of a subject in need thereof byinhalation, whereby as a resuit of said administering, (i) said insulin passes through thelung and enters the blood circulation, and (ii) elevated blood levels of insulin aresustained for at least 8 hours post administration.
42. The method of claim 41, wherein said non-naturally occurring hydrophilicpolymer is a polyalkylene glycol.
43. The method of claim 42, wherein said non-naturally occurring hydrophilicpol ymer i s pol yeth ylene gl ycol.
44. The method of claim 43, whereby elevated levels of insulin are sustained for atleast 10 hours post-administration.
45. The method of claim 43, whereby elevated levels of insulin are sustained for atleast 12 hours post-administration.
46. The method of claim 43, whereby further as a resuit of said administering, glucoselevels in said subject are suppressed for at least 10 hours post administration.
47. The method of claim 46, whereby further as a resuit of said administering, glucoselevels in said subject are suppressed for at least 12 hours post administration.
48. The method of claim 43, wherein said administering step comprises administeringsaid composition in aerosolized form.
49. The method of claim 43, further comprising the step of aerosolizing saidcomposition prior to administering. DUPLICATA 13136·
50. The method of claim 43, wherein said coupling step comprises covalentlycoupling insulin to polyethylene glycoi in a site-specific fashion.
51. The method of claim 43, wherein said coupling step comprises covalentlycoupling insulin to polyethylene glycoi in a random fashion.
52. The method of claim 43, wherein said conjugate when administered to the lung isfurther characterized by an absolute pulmonary bioavailability that is greater than that ofnative insulin.
53. The method of claim 43, wherein said coupling step comprises covalentlycoupling insulin to one or more molécules of end-capped polyethylene glycoi.
54. The method of claim 43, wherein said coupling step comprises covalentlycoupling insulin to one or more molécules of polyethylene glycoi selected from the groupconsisting of linear, branched, forked, and dumbbell polyethylene glycoi.
55. The method of claim 43, wherein said conjugate is absent a lipophilie moiety.
56. The method of claim 43, wherein said composition is absent a lipophiliecomponent.
57. The method of claim 43, wherein said coupling step comprises covalentlycoupling insulin to one or more molécules of polyethylene glycoi comprising abiodégradable linkage.
58. The method of claim 43, wherein said polyethylene glycoi comprises a number of(OCH7CH2) subunits selected from the group consisting of from about 2 to 300 subunits,from about 4 to 200 subunits, and from about 10 to 100 subunits.
59. The method of claim 43, wherein said polyethylene glycoi has a nominal averagemolecular weighl from about 200 to about 10,000 daltons. DUPLICATA 1 3136·* -68-
60. The method of daim 43, wherein said poiyethylene glycol has a nominal averagemolecular weight from about 200 to about 5,000 daltons.
61. The method of daim 43, wherein said poiyethylene glycol has a nominal averagemolecular weight from about 200 to about 2,000 daltons.
62. The method of daim 43, wherein said poiyethylene glycol has a nominal averagemolecular weight from about 200 to about 1,000 daltons.
63. The method of daim 43, wherein said coupling comprises coupling poiyethyleneglycol to insulin at one or more of its reactive amino sites.
64. The method of daim 63, wherein said poiyethylene glycol is coupled to insulin atmore or more of its reactive amino sites via a bond selected from the group consisting ofamide, urethane, and methylene amino.
65. The method of daim 63, wherein said coupling comprises reacting a poiyethyleneglycol having a terminal reactive group selected from the group consisting of N-hydroxysuccinimide active esters, active carbonates, aldéhydes, and acetals with one ormore reactive amino sites on insulin.
66. The method of daim 43, wherein said coupling results in a composition whereinat least about 75% of the B-lPhe sites on insulin are covalently coupled to poiyethyleneglycol.
67. The method of daim 43, wherein said coupling results in a composition whereinat least about 90% of the B-lPhe sites on insulin are covalently coupled to poiyethyleneglycol.
68. The method of daim 43, wherein said coupling results in a compositioncomprising a mixture of monomer and dimer conjugates of insulin. DUPLICATA -69- 13136·
69. The method of claim 68, wherein said coupiing results in a composition furthercomprising a trimer conjugate of insulin.
70. The method of ciaim 43, wherein said poiyethylene glycol comprises an activatedS linking moîety at one terminus suitable for covalent coupiing with insulin.
71. The method of claim 43, wherein said activated linking moiety comprises areactive functional group selected from the group consisting of N-hydroxysuccinimideactive esters, active carbonates, aldéhydes, and acetals. 10
72. The method of claim 70, wherein said linking moiety has a length of from about 2to about 20 atoms.
73. The method of claim 43, wherein said administering step comprises administering15 said composition by dry powder inhaler.
74. The method of claim 43, wherein said administering step comprises administeringsaid composition by a metered dose inhaler.
75. The method of claim 43, wherein said administering step comprises administering said composition by a nebulizer.
76. The method of ciaim 43, wherein said composition further comprises apharmaceutically acceptable excipient. 25
77. The method of claim 43, whereby as a resuit of administering said conjugatecomposition, sérum levcls of insulin that are at least 2 times greater than basai levels areachieved within 1 hour post administration. DUPLICATA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29242301P | 2001-05-21 | 2001-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA13136A true OA13136A (en) | 2006-12-13 |
Family
ID=23124608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300305A OA13136A (en) | 2001-05-21 | 2002-05-21 | Pulmonary administration of chemically modified insulin. |
Country Status (35)
Country | Link |
---|---|
US (3) | US6838076B2 (fr) |
EP (1) | EP1395294A4 (fr) |
JP (1) | JP2004535401A (fr) |
KR (1) | KR20030097876A (fr) |
CN (2) | CN101045166A (fr) |
AP (1) | AP1763A (fr) |
AR (1) | AR033903A1 (fr) |
AU (1) | AU2002303869B2 (fr) |
BG (1) | BG108494A (fr) |
BR (1) | BR0209896A (fr) |
CA (1) | CA2447236A1 (fr) |
CO (1) | CO5540371A2 (fr) |
CZ (1) | CZ20033182A3 (fr) |
EA (1) | EA007408B1 (fr) |
EC (1) | ECSP034855A (fr) |
GE (1) | GEP20063917B (fr) |
HR (1) | HRP20030949A2 (fr) |
HU (1) | HUP0400442A2 (fr) |
IL (2) | IL158862A0 (fr) |
IS (1) | IS7043A (fr) |
LT (1) | LT5153B (fr) |
LV (1) | LV13197B (fr) |
MA (1) | MA26185A1 (fr) |
MX (1) | MXPA03010649A (fr) |
MY (1) | MY137181A (fr) |
NO (1) | NO20035157D0 (fr) |
NZ (1) | NZ529572A (fr) |
OA (1) | OA13136A (fr) |
PL (1) | PL366911A1 (fr) |
SK (1) | SK15532003A3 (fr) |
TN (1) | TNSN03116A1 (fr) |
TR (1) | TR200400295T2 (fr) |
WO (1) | WO2002094200A2 (fr) |
YU (1) | YU98503A (fr) |
ZA (1) | ZA200309085B (fr) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
US20060171899A1 (en) * | 1998-12-10 | 2006-08-03 | Akwete Adjei | Water-stabilized aerosol formulation system and method of making |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
AU2002303869B2 (en) * | 2001-05-21 | 2007-08-16 | Novartis Ag | Pulmonary administration of chemically modified insulin |
NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
DE60231428D1 (de) * | 2001-12-21 | 2009-04-16 | 3M Innovative Properties Co | Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff |
ES2300568T3 (es) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | Aparato de inhalacion. |
US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
EP2298278B1 (fr) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prévention et réduction de perte sanguine et la réponse inflammatoire |
EP1596887B1 (fr) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Conjugues de groupe fonctionnel a facteur polymerique viii |
EP1613272B1 (fr) * | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Procede de preparation de conjugues de proteines specifiques de site |
EP1491554A1 (fr) * | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | Solubles gp130-dimeres modifiée avec du PEG pour utilisation comme medicament |
CA3050564A1 (fr) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Inhibiteurs de protease poly-pegylee |
AU2004268144A1 (en) * | 2003-08-29 | 2005-03-10 | Dyax Corp. | Modified protease inhibitors |
GB0328629D0 (en) * | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
WO2005115477A2 (fr) | 2004-04-13 | 2005-12-08 | Quintessence Biosciences, Inc. | Conjugues de ribonuclease non naturelle utilises en tant qu'agents cytotoxiques |
CN101027318B (zh) * | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物,制剂及其用途 |
CA2575692C (fr) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalyse de la synthese de dicetopiperazine |
BR122019022692B1 (pt) | 2004-08-23 | 2023-01-10 | Mannkind Corporation | Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo |
US20060046852A1 (en) * | 2004-08-26 | 2006-03-02 | Rowe Richard E | Wide area gaming system |
US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US8245758B2 (en) * | 2006-10-30 | 2012-08-21 | GM Global Technology Operations LLC | Coulomb damped disc brake rotor and method of manufacturing |
WO2006076277A1 (fr) * | 2005-01-10 | 2006-07-20 | Nektar Therapeutics | Compositions et methodes permettant d'augmenter la biodisponibilite d'insuline administree par voie pulmonaire |
WO2006079641A2 (fr) * | 2005-01-27 | 2006-08-03 | Novo Nordisk A/S | Derives d'insuline conjugues avec des polymeres ramifies structurellement bien definis |
TWI376234B (en) * | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
JP5410020B2 (ja) | 2005-02-02 | 2014-02-05 | ノヴォ ノルディスク アー/エス | インスリン誘導体 |
EP2256130B1 (fr) | 2005-02-02 | 2013-09-25 | Novo Nordisk A/S | Nouveaux dérivés d'insuline |
EP1863840A1 (fr) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Insuline monocatenaire pegylee |
US20060271011A1 (en) * | 2005-05-25 | 2006-11-30 | Mock Bradley D | Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced |
HUE028691T2 (en) * | 2005-09-14 | 2016-12-28 | Mannkind Corp | A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients |
US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
US20080033763A1 (en) * | 2005-11-30 | 2008-02-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems related to receiving nutraceutical associated information |
US10296720B2 (en) * | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
US20070289258A1 (en) * | 2006-06-14 | 2007-12-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Individualized pharmaceutical selection and packaging |
US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
US20070136092A1 (en) * | 2005-11-30 | 2007-06-14 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
US7927787B2 (en) * | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
US20080004905A1 (en) * | 2006-06-28 | 2008-01-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Methods and systems for analysis of nutraceutical associated components |
US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
US8340944B2 (en) * | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
US20080052114A1 (en) * | 2005-11-30 | 2008-02-28 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational systems and methods related to nutraceuticals |
US7827042B2 (en) * | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
US20070174128A1 (en) * | 2005-11-30 | 2007-07-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging |
US20070124219A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems related to individualized nutraceutical selection and packaging |
US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
US20070124176A1 (en) * | 2005-11-30 | 2007-05-31 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US20080103746A1 (en) * | 2005-11-30 | 2008-05-01 | Searete Llc, A Limited Liability Corporation | Systems and methods for pathogen detection and response |
US20080114577A1 (en) * | 2005-11-30 | 2008-05-15 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational methods and systems associated with nutraceutical related assays |
JP5738516B2 (ja) | 2005-12-30 | 2015-06-24 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | 心機能改善のためのニューレグリンの徐放 |
EP1986679B1 (fr) | 2006-02-22 | 2017-10-25 | MannKind Corporation | Procédé pour améliorer les propriétés pharmaceutiques de microparticules comprenant de la dicétopipérazine et un agent actif |
US20070292404A1 (en) * | 2006-03-27 | 2007-12-20 | Biosynexus Incorporated | Antimicrobial polymer conjugates |
JP2009541333A (ja) | 2006-06-23 | 2009-11-26 | クインテセンス バイオサイエンシーズ インコーポレーティッド | 修飾リボヌクレアーゼ |
ATE480568T1 (de) | 2006-06-30 | 2010-09-15 | Conaris Res Inst Ag | Verbesserte sgp 130fc dimere |
EP2049151A4 (fr) * | 2006-07-17 | 2010-03-24 | Quintessence Biosciences Inc | Méthodes et compositions pour le traitement du cancer |
EP2049149B1 (fr) | 2006-07-31 | 2015-04-15 | Novo Nordisk A/S | Insulines pegylées à extensions |
WO2008019036A2 (fr) * | 2006-08-04 | 2008-02-14 | Pharmathene Inc. | Butyrylcholinestérase recombinante à demi-vie longue |
JP5864834B2 (ja) | 2006-09-22 | 2016-02-17 | ノボ・ノルデイスク・エー/エス | プロテアーゼ耐性のインスリンアナログ |
US8110655B2 (en) | 2006-11-13 | 2012-02-07 | Auxagen, Inc. | Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor |
WO2008084051A1 (fr) * | 2007-01-12 | 2008-07-17 | Novo Nordisk A/S | Mélanges d'insuline pégylée et d'insuline à action rapide pour une administration pulmonaire |
US20140011964A1 (en) | 2007-02-28 | 2014-01-09 | Serina Therapeutics, Inc. | Activated Polyoxazolines and Conjugates and Compositions Comprising the Same |
JP5615558B2 (ja) * | 2007-02-28 | 2014-10-29 | セリナ・セラピユーテイツクス・インコーポレーテツド | 活性ポリオキサゾリンおよびそれを含む組成物 |
US9387176B2 (en) | 2007-04-30 | 2016-07-12 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
WO2009020434A1 (fr) * | 2007-08-07 | 2009-02-12 | Nanomaterials Technology Pte Ltd | Procédé de fabrication de particules de protéine microdimensionnée |
US8946201B2 (en) * | 2007-08-27 | 2015-02-03 | Saint Louis University | Methods for inhibiting TGF-β |
US8697062B2 (en) * | 2007-10-08 | 2014-04-15 | Quintessence Biosciences, Inc. | Compositions and methods for ribonuclease-based therapeutics |
WO2009050738A2 (fr) | 2007-10-16 | 2009-04-23 | Biocon Limited | Composition pharmaceutique solide administrable par voie orale et procédé associé |
CN101795680A (zh) * | 2007-11-16 | 2010-08-04 | 波苏蛋白试剂公司 | 稳定蛋白质的辅剂 |
JP5762001B2 (ja) | 2008-03-14 | 2015-08-12 | ノボ・ノルデイスク・エー/エス | プロテアーゼ安定化インスリンアナログ |
PT2254906T (pt) | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
AR072114A1 (es) | 2008-06-13 | 2010-08-04 | Mannkind Corp | Un inhalador de polvo seco y sistema para suministro de farmacos |
US8488661B2 (en) * | 2008-06-13 | 2013-07-16 | Verizon Patent And Licensing Inc. | Systems and methods for data streaming |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
BRPI0914308B8 (pt) | 2008-06-20 | 2021-06-22 | Mannkind Corp | sistema de inalação |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
CN102159219B (zh) * | 2008-09-16 | 2015-06-24 | 圣路易斯大学 | 提高转化生长因子-β信号发送的方法 |
MX2011003117A (es) * | 2008-09-19 | 2011-04-21 | Nektar Therapeutics | Conjugados polimericos de peptidos terapeuticos. |
EP2344200A2 (fr) * | 2008-09-19 | 2011-07-20 | Nektar Therapeutics | Peptides thérapeutiques modifiés, procédés pour les préparer et les utiliser |
EP2334695B1 (fr) | 2008-10-01 | 2015-12-23 | Quintessence Biosciences, Inc. | Ribonucléases thérapeutiques |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
WO2010078373A1 (fr) | 2008-12-29 | 2010-07-08 | Mannkind Corporation | Analogues substitués de dicétopipérazine pour une utilisation en tant qu'agents d'administration de médicaments |
AU2010203712A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
CA2754595C (fr) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Appareil, systeme et procede de mesure de resistance d'un inhalateur |
KR101875969B1 (ko) | 2009-06-12 | 2018-07-06 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
SG178195A1 (en) * | 2009-07-31 | 2012-03-29 | Sanofi Aventis Deutschland | Long acting insulin composition |
CA2769340C (fr) | 2009-07-31 | 2018-09-11 | Harald Rau | Promedicaments contenant un conjugue associant une sequence de liaison et de l'insuline |
WO2011059609A2 (fr) | 2009-10-13 | 2011-05-19 | The Regents Of The University Of Michigan | Compositions de dendrimères et procédés de synthèse |
EP2496295A1 (fr) | 2009-11-03 | 2012-09-12 | MannKind Corporation | Appareil et méthode de simulation d'efforts d'inhalation |
WO2011084145A2 (fr) | 2009-12-21 | 2011-07-14 | Pharmathene, Inc. | Butyrylcholinestérases recombinantes et produits de troncature de ceux-ci |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
RU2571331C1 (ru) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
EP2438930A1 (fr) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Promédicaments comprenant un conjugué de liaison d'exendine |
BR112013017080A8 (pt) | 2011-01-06 | 2023-05-09 | Dyax Corp | Anticorpo ou fragmento funcional do mesmo que se liga a forma ativa de calicreína do plasma humano, composiçao farmacêutica e método de detecçao de calicreína do plasma em um paciente |
US9187547B2 (en) | 2011-03-15 | 2015-11-17 | Novo Nordisk A/S | Human insulin analogues and derivatives comprising cysteine substitutions |
CN102675452B (zh) | 2011-03-17 | 2015-09-16 | 重庆富进生物医药有限公司 | 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物 |
JP6133270B2 (ja) | 2011-04-01 | 2017-05-24 | マンカインド コーポレイション | 薬剤カートリッジのためのブリスター包装 |
WO2012174472A1 (fr) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | Microparticules de dicétopipérazine de capacité élevée |
JP6018640B2 (ja) | 2011-10-24 | 2016-11-02 | マンカインド コーポレイション | 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム |
CN102504022A (zh) * | 2011-11-30 | 2012-06-20 | 苏州元基生物技术有限公司 | 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法 |
CA2870313A1 (fr) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Formulations a base d'insuline |
US9457096B2 (en) | 2012-07-06 | 2016-10-04 | Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) | Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery |
SG11201500218VA (en) | 2012-07-12 | 2015-03-30 | Mannkind Corp | Dry powder drug delivery systems and methods |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
JP6735561B2 (ja) | 2012-12-03 | 2020-08-05 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | O−グリコシル化カルボキシ末端部分(ctp)ペプチド系のインスリンおよびインスリン類似体 |
WO2014144895A1 (fr) | 2013-03-15 | 2014-09-18 | Mannkind Corporation | Compositions de dicétopipérazine microcristallines et procédés |
AU2014290438B2 (en) | 2013-07-18 | 2019-11-07 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
WO2015021064A1 (fr) | 2013-08-05 | 2015-02-12 | Mannkind Corporation | Appareil d'insufflation et procédés |
JP6822839B2 (ja) | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
JP6775513B2 (ja) | 2014-12-01 | 2020-10-28 | フェリング・ベー・フェー | 選択的il−6−トランス−シグナル伝達阻害剤の投与 |
BR112018011622A2 (pt) | 2015-12-11 | 2018-11-27 | Dyax Corp | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae |
EP3442998A4 (fr) | 2016-04-12 | 2020-04-01 | Cell And Molecular Tissue Engineering, LLC | Systèmes, procédés et produits permettant de réduire au minimum les réactions tissulaires et les lésions tissulaires au niveau d'un site de perfusion |
WO2018085021A1 (fr) * | 2016-11-02 | 2018-05-11 | Dow Global Technologies Llc | Dispositif d'odorisation d'air en gel non aqueux solide |
CN110087674B (zh) | 2016-12-16 | 2023-01-03 | 诺和诺德股份有限公司 | 含胰岛素的药物组合物 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
DOP1982004086A (es) | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
US4652548A (en) | 1981-08-27 | 1987-03-24 | Eli Lilly And Company | Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin |
US4654324A (en) | 1981-08-27 | 1987-03-31 | Eli Lilly And Company | Human proinsulin pharmaceutical formulations |
US4839341A (en) | 1984-05-29 | 1989-06-13 | Eli Lilly And Company | Stabilized insulin formulations |
US5342940A (en) | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
ES2085297T3 (es) | 1989-05-27 | 1996-06-01 | Sumitomo Pharma | Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada. |
US5652214A (en) * | 1989-06-05 | 1997-07-29 | Cephalon, Inc. | Treating disorders by application of insulin-like growth factors and analogs |
US5766897A (en) * | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
EP0761683B1 (fr) | 1994-05-20 | 2005-02-02 | Hisamitsu Pharmaceutical Co., Inc. | Proteine ou polypeptide, procede et intermediaires permettant leur preparation |
US5730990A (en) | 1994-06-24 | 1998-03-24 | Enzon, Inc. | Non-antigenic amine derived polymers and polymer conjugates |
US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
DE19628143A1 (de) | 1996-07-12 | 1998-01-15 | Basf Ag | Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion |
AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
HUP0004096A3 (en) | 1997-10-24 | 2001-12-28 | Novo Nordisk As | Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
KR20010074777A (ko) | 1998-07-27 | 2001-08-09 | 추후제출 | 활성제의 폐를 통한 전달 |
WO2000033866A1 (fr) * | 1998-12-04 | 2000-06-15 | Provalis Uk Limited | Composition pharmaceutique contenant de l'insuline |
EP1146860A4 (fr) | 1999-01-08 | 2002-07-03 | Emisphere Tech Inc | Agents d'administration polymeres et composes d'agents d'administration |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US7169889B1 (en) * | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
US6323311B1 (en) * | 1999-09-22 | 2001-11-27 | University Of Utah Research Foundation | Synthesis of insulin derivatives |
WO2001068141A2 (fr) | 2000-03-17 | 2001-09-20 | Maxygen Aps | Dispersions de conjugues polypeptidiques |
US20020168323A1 (en) * | 2001-05-11 | 2002-11-14 | Igor Gonda | Optimization of the molecular properties and formulation of proteins delivered by inhalation |
AU2002303869B2 (en) * | 2001-05-21 | 2007-08-16 | Novartis Ag | Pulmonary administration of chemically modified insulin |
US6828297B2 (en) | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
ES2307779T3 (es) * | 2001-08-16 | 2008-12-01 | Baxter International Inc. | Formulaciones de microparticulas a base de propelentes. |
-
2002
- 2002-05-21 AU AU2002303869A patent/AU2002303869B2/en not_active Ceased
- 2002-05-21 CN CNA2007100855527A patent/CN101045166A/zh active Pending
- 2002-05-21 TR TR2004/00295T patent/TR200400295T2/xx unknown
- 2002-05-21 EP EP02731931A patent/EP1395294A4/fr not_active Withdrawn
- 2002-05-21 HU HU0400442A patent/HUP0400442A2/hu unknown
- 2002-05-21 JP JP2002590921A patent/JP2004535401A/ja active Pending
- 2002-05-21 YU YU98503A patent/YU98503A/sh unknown
- 2002-05-21 CZ CZ20033182A patent/CZ20033182A3/cs unknown
- 2002-05-21 SK SK1553-2003A patent/SK15532003A3/sk not_active Application Discontinuation
- 2002-05-21 KR KR10-2003-7014954A patent/KR20030097876A/ko not_active Application Discontinuation
- 2002-05-21 PL PL02366911A patent/PL366911A1/xx not_active Application Discontinuation
- 2002-05-21 EA EA200301222A patent/EA007408B1/ru not_active IP Right Cessation
- 2002-05-21 WO PCT/US2002/016464 patent/WO2002094200A2/fr active IP Right Grant
- 2002-05-21 MY MYPI20021867A patent/MY137181A/en unknown
- 2002-05-21 NZ NZ529572A patent/NZ529572A/en unknown
- 2002-05-21 CN CNB028103556A patent/CN1314445C/zh not_active Expired - Fee Related
- 2002-05-21 GE GE5398A patent/GEP20063917B/en unknown
- 2002-05-21 AR ARP020101877A patent/AR033903A1/es not_active Application Discontinuation
- 2002-05-21 BR BR0209896-2A patent/BR0209896A/pt not_active Application Discontinuation
- 2002-05-21 US US10/154,057 patent/US6838076B2/en not_active Expired - Lifetime
- 2002-05-21 OA OA1200300305A patent/OA13136A/en unknown
- 2002-05-21 MX MXPA03010649A patent/MXPA03010649A/es active IP Right Grant
- 2002-05-21 CA CA002447236A patent/CA2447236A1/fr not_active Abandoned
- 2002-05-21 AP APAP/P/2003/002918A patent/AP1763A/en active
- 2002-05-21 IL IL15886202A patent/IL158862A0/xx unknown
-
2003
- 2003-04-01 US US10/405,190 patent/US6890518B2/en not_active Expired - Fee Related
- 2003-07-08 TN TNPCT/US2002/016464A patent/TNSN03116A1/en unknown
- 2003-11-13 IL IL158862A patent/IL158862A/en not_active IP Right Cessation
- 2003-11-19 IS IS7043A patent/IS7043A/is unknown
- 2003-11-20 NO NO20035157A patent/NO20035157D0/no unknown
- 2003-11-20 CO CO03102566A patent/CO5540371A2/es unknown
- 2003-11-20 EC EC2003004855A patent/ECSP034855A/es unknown
- 2003-11-21 LV LVP-03-131A patent/LV13197B/en unknown
- 2003-11-21 MA MA27413A patent/MA26185A1/fr unknown
- 2003-11-21 HR HR20030949A patent/HRP20030949A2/xx not_active Application Discontinuation
- 2003-12-17 LT LT2003107A patent/LT5153B/lt not_active IP Right Cessation
- 2003-12-22 BG BG108494A patent/BG108494A/xx unknown
-
2004
- 2004-11-02 US US10/980,652 patent/US20050152848A1/en not_active Abandoned
- 2004-11-21 ZA ZA200309085A patent/ZA200309085B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
OA13136A (en) | Pulmonary administration of chemically modified insulin. | |
AU2002303869A1 (en) | Pulmonary administration of chemically modified insulin | |
EP2049149B1 (fr) | Insulines pegylées à extensions | |
JP5721432B2 (ja) | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン | |
EP2459171B1 (fr) | Composition d'insuline à action prolongée | |
JP5688969B2 (ja) | プロテアーゼに対して安定しているペグ化インスリンアナログ | |
EP2364735A2 (fr) | Conjugé de GLP-1 et de PEG ramafié | |
WO2010033220A2 (fr) | Peptides thérapeutiques modifiés, procédés pour les préparer et les utiliser | |
EP2017288A1 (fr) | Analogues de l'insuline pégylés, stabilisés à la protéase | |
US20220152155A1 (en) | Formulations for bovine granulocyte colony stimulating factor and variants thereof | |
WO2008084051A1 (fr) | Mélanges d'insuline pégylée et d'insuline à action rapide pour une administration pulmonaire | |
US20080159964A1 (en) | Use of adenosine deaminase for treating pulmonary disease |